The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer develops in the cells of the cervix. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, play a role in causing most of the cervical cancers. The disease begins when healthy cells acquire mutation leading to the uncontrolled growth of cells. These cells form a tumor which invades the nearby tissues. Squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas are three types of cervical cancers. Squamous cell carcinomas develop from cells in the exocervix while adenocarcinomas develop from gland cells. The cancer cells are said to have features of squamous cells under the microscope. Adenosquamous carcinomas feature both squamous cell carcinomas and adenocarcinomas. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are various treatment options for cervical cancer. Cystoscopy, proctoscopy, examination under anesthesia, and imaging studies such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), intravenous urography, and Positron Emission Tomography (PET scan) are used of the diagnosis of cervical cancer.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5834
The cervical cancer treatment market is mainly driven by the increasing prevalence of cervical cancer and increasing awareness about cervical cancer among women. Furthermore, the increasing demand for early diagnosis and treatment of cervical cancer is also expected to fuel the growth of the market during the review period. However, the high cost of treatment also fuels the growth of the market. The World Health Organization (WHO) stated that cancer was the leading cause of the total number of deaths globally in 2015 and was responsible for 8.8 million deaths.
Global Cervical Cancer Treatment market is expected to grow at a CAGR of 6.5% during the forecast period.
Major Players in the Cervical Cancer Treatment Market Some of the key players in the global market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others. Regional Analysis The American market for cervical cancer treatment is accelerated by the growing demand for new treatments for cancer in women and presence of major players manufacturing chemotherapy in the market. Additionally, the increasing number of patients and the rising demand for new drugs and therapies also drive the growth of the market. In the U.S., women are now becoming aware of risk factors associated with the disease and focus on preventive care. Therefore, the increasing awareness about the women also fuels the growth of the market. The Canadian market is driven by the increase in the demand for new imaging devices and treatment options for cancer, while the South American market is expected to exhibit a growth with an increase in healthcare expenditure. The European market is boosted by extensive research and development in oncology and the increasing number of cancer care centers and research institutes. Furthermore, other factors boosting the market growth are well-developed healthcare infrastructure and rising government support for research in cancer treatment. The cervical cancer treatment market in Asia Pacific is expected to show the fastest growth with the rapid development of the medical devices sector, increasing healthcare expenditure, and focus on women healthcare. Furthermore, increasing government initiatives such as healthcare programs for women, awareness about breast cancer, and its diagnosis are expected to boost the market during the review period. The Middle East and Africa, cervical cancer treatment market, demonstrate a steady growth in the market due to various factors such as low penetration of technology and increasing use of treatment services. Segmentation The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user. On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others. Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others. The radiation therapy is further segmented into external beam radiation and brachytherapy. Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others. Targeted therapy is further segmented into bevacizumab and pazopanib. Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone. On the basis of end-user, the market is segmented into cancer care centers, diagnostic centers, pharmacies, and others. Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cervical-cancer-treatment-market-5834
Comments